IBI343

Phase 3Small molecule

Innovent Biologics (Suzhou) Co. Ltd.

IBI343 is one of 130 small molecule programs targeting Advanced Pancreatic Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

129

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Pancreatic CancerRecruiting

Locally Advanced Unresectable or Metastatic Solid TumorsRecruiting

Gastroesophageal Junction AdenocarcinomaRecruiting

Pancreatic CancerRecruiting

Gastric CancerRecruiting

Advanced Pancreatic CancerPreclinical

Recruiting

Locally Advanced Unresectable or Metastatic Solid TumorsPhase 1

Recruiting

Gastroesophageal Junction AdenocarcinomaPhase 3

Recruiting

Pancreatic CancerPhase 3

Recruiting

Gastric CancerPhase 2

Recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

IBI343

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

3 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 5

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06238843

Phase 1Recruiting

Locally Advanced Unresectable or Metastatic Solid Tumors

NCT05458219

PreclinicalRecruiting

Advanced Pancreatic Cancer

NCT07692750

Q1 2028

Phase 2Recruiting

Pancreatic Cancer

NCT06770439

Q2 2028

PreclinicalRecruiting

Gastric Cancer

NCT07025889

Phase 3Recruiting

Pancreatic Cancer

NCT07066098

Clinical

Trials by Indication[1]

Pancreatic Cancer3 trials

IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer

Not yet recruiting·ZZhejiang University·Phase 2·NCT07415525·40 enrolled

IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer

Recruiting·ZZhejiang University·Phase 2·NCT06770439·64 enrolled

A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)

Recruiting· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT07066098·201 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT06238843·450 enrolled

Locally Advanced Unresectable or Metastatic Solid Tumors1 trial

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Recruiting· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05458219·470 enrolled

Gastric Cancer1 trial

IBI343 Combined With Sintilimab Plus Chemotherapy in Previously Untreated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Dragon15)

Recruiting·RRuijin Hospital·Preclinical·NCT07025889·55 enrolled

Advanced Pancreatic Cancer1 trial

A Phase Ib/II Study to Evaluate the Safety, Tolerability and Efficacy of IBI343 in Combination With Chemotherapy in Subjects With Advanced Pancreatic Cancer

Recruiting·ZZhejiang Cancer Hospital·Preclinical·NCT07692750·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for IBI343. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IBI343 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IBI343. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Innovent Biologics (Suzhou) Co. Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Innovent Biologics (Suzhou) Co. Ltd.

IBI343

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Q2 2028

Trials by Indication[1]

Pancreatic Cancer3 trials

Gastroesophageal Junction Adenocarcinoma1 trial

Locally Advanced Unresectable or Metastatic Solid Tumors1 trial

Gastric Cancer1 trial

Advanced Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News